Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 26


Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort.

Esgueva R, Perner S, J LaFargue C, Scheble V, Stephan C, Lein M, Fritzsche FR, Dietel M, Kristiansen G, Rubin MA.

Mod Pathol. 2010 Apr;23(4):539-46. doi: 10.1038/modpathol.2009.193. Epub 2010 Jan 29.


N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.

Pflueger D, Rickman DS, Sboner A, Perner S, LaFargue CJ, Svensson MA, Moss BJ, Kitabayashi N, Pan Y, de la Taille A, Kuefer R, Tewari AK, Demichelis F, Chee MS, Gerstein MB, Rubin MA.

Neoplasia. 2009 Aug;11(8):804-11.


Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.

Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT, Kearney MC, Johnson LA, Tang JM, Chinnaiyan AM, Rubin MA, Sanda MG.

Clin Cancer Res. 2009 Jul 15;15(14):4706-11. doi: 10.1158/1078-0432.CCR-08-2927. Epub 2009 Jul 7.


ETS gene fusions in prostate cancer: from discovery to daily clinical practice.

Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, Schalken JA.

Eur Urol. 2009 Aug;56(2):275-86. doi: 10.1016/j.eururo.2009.04.036. Epub 2009 Apr 24. Review.


Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.

Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A, Palanisamy N, Tomlins SA, Chinnaiyan AM, Shah RB.

Mod Pathol. 2009 Aug;22(8):1083-93. doi: 10.1038/modpathol.2009.69. Epub 2009 May 1.


Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.

Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP.

Nat Genet. 2009 May;41(5):619-24. doi: 10.1038/ng.370. Epub 2009 Apr 26.


Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, Oommen NB, Hawche G, Jameson C, Thompson E, Sipkema R, Carden CP, Parker C, Dearnaley D, Kaye SB, Cooper CS, Molina A, Cox ME, Terstappen LW, de Bono JS.

Cancer Res. 2009 Apr 1;69(7):2912-8. doi: 10.1158/0008-5472.CAN-08-3667.


A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer.

Han B, Mehra R, Dhanasekaran SM, Yu J, Menon A, Lonigro RJ, Wang X, Gong Y, Wang L, Shankar S, Laxman B, Shah RB, Varambally S, Palanisamy N, Tomlins SA, Kumar-Sinha C, Chinnaiyan AM.

Cancer Res. 2008 Sep 15;68(18):7629-37. doi: 10.1158/0008-5472.CAN-08-2014.


Recurrent gene fusions in prostate cancer.

Kumar-Sinha C, Tomlins SA, Chinnaiyan AM.

Nat Rev Cancer. 2008 Jul;8(7):497-511. doi: 10.1038/nrc2402. Epub 2008 Jun 19. Review.


Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications.

Mosquera JM, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD, Paris PL, Simko J, Bismar TA, Ayala G, Shah RB, Loda M, Rubin MA.

Clin Cancer Res. 2008 Jun 1;14(11):3380-5. doi: 10.1158/1078-0432.CCR-07-5194.


Role of the TMPRSS2-ERG gene fusion in prostate cancer.

Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, Mehra R, Chinnaiyan AM.

Neoplasia. 2008 Feb;10(2):177-88.


Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer.

Yu J, Cao Q, Mehra R, Laxman B, Yu J, Tomlins SA, Creighton CJ, Dhanasekaran SM, Shen R, Chen G, Morris DS, Marquez VE, Shah RB, Ghosh D, Varambally S, Chinnaiyan AM.

Cancer Cell. 2007 Nov;12(5):419-31.


TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications.

Barry M, Perner S, Demichelis F, Rubin MA.

Urology. 2007 Oct;70(4):630-3.


Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases.

Mehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ, Shen R, Montie JE, Chinnaiyan AM, Shah RB.

Cancer Res. 2007 Sep 1;67(17):7991-5.


TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.

Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA.

Am J Surg Pathol. 2007 Jun;31(6):882-8.


Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.

Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, Perner S, Tomlins S, Tchinda J, Laxman B, Vessella RL, Beroukhim R, Lee C, Chinnaiyan AM, Rubin MA.

Neoplasia. 2007 Mar;9(3):200-6.


Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer.

Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM, Shah RB.

Mod Pathol. 2007 May;20(5):538-44. Epub 2007 Mar 2.


TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.

Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG, Kuefer R, Vessella R, Sun XW, Meyerson M, Lee C, Sellers WR, Chinnaiyan AM, Rubin MA.

Cancer Res. 2006 Sep 1;66(17):8337-41.


Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM.

Science. 2005 Oct 28;310(5748):644-8.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk